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Abstract
Introduction Autologous chondrocyte transplantation (ACT) is
a routine technique to regenerate focal cartilage lesions.
However, patients with osteoarthritis (OA) are lacking an
appropriate long-lasting treatment alternative, partly since it is
not known if chondrocytes from OA patients have the same
chondrogenic differentiation potential as chondrocytes from
donors not affected by OA.
Methods Articular chondrocytes from patients with OA
undergoing total knee replacement (Mankin Score > 3, Ahlbäck
Score > 2) and from patients undergoing ACT, here referred to
as normal donors (ND), were isolated applying protocols used
for ACT. Their chondrogenic differentiation potential was
evaluated both in high-density pellet and scaffold (Hyaff-11)
cultures by histological proteoglycan assessment (Bern Score)
and immunohistochemistry for collagen types I and II.
Chondrocytes cultured in monolayer and scaffolds were
subjected to gene expression profiling using genome-wide
oligonucleotide microarrays. Expression data were verified by
using real-time PCR.
Results Chondrocytes from ND and OA donors demonstrated
accumulation of comparable amounts of cartilage matrix
components, including sulphated proteoglycans and collagen
types I and II. The mRNA expression of cartilage markers
(ACAN, COL2A1, COMP, CRTL1, SOX9) and genes involved
in matrix synthesis (BGN, CILP2, COL9A2, COL11A1, TIMP4)
was highly induced in 3D cultures of chondrocytes from both
donor groups. Genes associated with hypertrophic or OA
cartilage (ALPL, COL1A1, COL3A1, COL10A1, MMP13,
POSTN, PTH1R, RUNX2) were not significantly regulated
between the two groups of donors. The expression of 661
genes, including COMP,  FN1, and SOX9, was differentially
regulated between OA and ND chondrocytes cultured in
monolayer. During scaffold culture, the differences diminished
between the OA and ND chondrocytes, and only 184 genes
were differentially regulated.
Conclusions Only few genes were differentially expressed
between OA and ND chondrocytes in Hyaff-11 culture. The risk
of differentiation into hypertrophic cartilage does not seem to be
increased for OA chondrocytes. Our findings suggest that the
chondrogenic capacity is not significantly affected by OA, and
OA chondrocytes fulfill the requirements for matrix-associated
ACT.
3D: three-dimensional; ACAN: aggrecan; ACT: autologous chondrocyte transplantation; ADAMTS: a disintegrin and metalloproteinase with throm-
bospondin motifs; ASPN: asporin; BGN: biglycan; BMP: bone morphogenetic protein; BSA: bovine serum albumin; CILP2: cartilage intermediate 
layer protein 2; COL1A1: collagen type Iα1; COL2A1: collagen type IIα1; COL3A1: collagen type IIIα1; COL9A2: collagen type IXα3; COL10A1: 
collagen type Xα1; COL11A1: collagen type XIα2; COMP: cartilage oligomeric matrix protein; CRTL1: cartilage link protein 1; DMEM: Dulbecco's 
Modified Eagle Medium; DPT: dermatopontin; DST: dystonin; ECM: extracellular matrix; FC: fold change; FGFR: fibroblast growth factor receptor; 
FMOD: fibromodulin; FN1: fibronectin 1; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HOX: homeobox; IGF: insulin-like growth factor; IL: 
interleukin; ML: monolayer; MMP: matrix metalloproteinase; ND: normal/healthy donor; OA: osteoarthritis; PBS: phosphate-buffered saline; PCR: 
polymerase chain reaction; RUNX2: runt-related transcription factor; SOX: SRY (sex determining region Y)-box; TGF: transforming growth factor; 
TIMP: tissue inhibitor of metalloproteinase; TNC: tenascin C; TNF: tumor necrosis factor.Arthritis Research & Therapy    Vol 11 No 5    Dehne et al.
Page 2 of 14
(page number not for citation purposes)
Introduction
The regenerative capacity of articular cartilage is very limited
and injuries that do not penetrate the subchondral bone do not
self-repair in adults. This low potential for regeneration has
resulted in the development of a number of techniques
intended to restore hyaline cartilage defects [1]. One treat-
ment option is autologous chondrocyte transplantation (ACT)
developed by Brittberg and colleagues in the early 1990s [2].
This technique is based on the isolation of chondrocytes from
a minor load-bearing area of the knee, cell expansion and re-
transplantation as cell suspensions. This first generation of
cell-based treatment has been followed by a second genera-
tion, consisting of culture-expanded chondrocytes seeded into
a biodegradable scaffold before implantation [3-5].
Today, esterified hyaluronic acid-based scaffolds, collagen
membranes and gels, and fibrin-polymer scaffolds are used as
delivery vehicles for second generation ACT. These scaffolds
are resorbed in vivo allowing complete replacement of the
implant with newly formed tissue and also support re-differen-
tiation of the chondrocytes [3,5-7]. Advantages of this sec-
ond-generation technique include a more uniform distribution
of the cells and prevention of cells escaping into the articular
cavity. Another advantage is the potential for treating larger
defects [8]. This is of special importance for patients with
osteoarthritis (OA), who today are lacking an appropriate long-
lasting treatment alternative [9].
Several articles have demonstrated phenotypical alterations in
OA chondrocytes in vivo compared with normal chondro-
cytes. The expression of genes belonging to hypertrophic car-
tilage (collagen type X) and more primitive cartilage (collagen
type I and collagen type III) was increased, while the expres-
sion of genes characteristic for a mature articular cartilage
phenotype was significantly decreased (aggrecan,cartilage
link protein 1,SRY (sex determining region Y)-box 9) in com-
parison with normal cartilage [10,11]. Some articles reported
that these OA-related alterations influence bioactivity and
matrix gene expression negatively when cultured in vitro
[12,13]. Others demonstrated that OA chondrocytes display
a good proliferation potential and were able to re-differentiate
resulting in a matrix rich in proteoglycans and collagen type II
[14,15]. Such conflicting data encouraged us to investigate
more thoroughly the chondrogenic potential of OA chondro-
cytes for possible use in second-generation ACT.
In this study, the chondrogenic capacity of expanded chondro-
cytes from normal and OA donors was examined compara-
tively to investigate whether OA chondrocytes are suited for
cartilage tissue engineering approaches in OA. Therefore, pro-
tocols as used for ACT were applied for chondrocyte prepara-
tion and expansion. The differentiation potential was
histologically analyzed after 14 days in high-density pellet and
hyaluronan-based scaffold cultures. Aiming on a comprehen-
sive molecular analysis of the differentiation process of OA
chondrocytes, expanded chondrocytes and chondrocytes in
scaffold cultures were subjected to gene expression profiling
using genome-wide Affymetrix oligonucleotide microarrays.
Materials and methods
Biopsy collection and Mankin scoring
Patients with OA were selected for the study if they fulfilled
five criteria: symptoms of severe OA, undergoing total knee
replacement, radiological evidence of OA, OA grade 2 to 3
according to Ahlbäck score, and exhibiting a Mankin score
above 3. Articular cartilage from three donors (one female and
two males) was collected based on these criteria. The donors
age ranged from 60 to 64 years (average 62 years) with a
Mankin score of 3 to 7. Control patients were selected for
inclusion in the study if they had no pre-existing history of OA
symptoms, macroscopically healthy cartilage, and were under-
going ACT treatment (these donors are referred to as normal
donors (ND)). ND articular cartilage biopsies were obtained
from three donors (age range 46 to 52 years, average age 50
years, one female and two males). The biopsies were trans-
ported to the cell culture laboratory in sterile saline solution
(0.9% sodium chloride; Fresenius Kabi, Uppsala, Sweden)
supplemented with gentamicin sulphate (50 mg/l; Gibco,
Paisley, Renfrewshire, UK) and amphotericin B (250 μg/ml;
Gibco, Paisley, Renfrewshire, UK). One part of each OA carti-
lage biopsy was processed for histology, stained with
Safranin-O and Alcian Blue van Gieson, blinded and scored in
accordance with a modified (biopsies without subchondral
bone) Mankin scale, with a maximum score of 13. All six
donors were used to carry out the following investigations
(Figure 1). The donation of cartilage was approved by the eth-
ical committee at the Medical Faculty at Gothenburg Univer-
sity (ethical permission number S 040-01). Informed consent
had been obtained from cartilage donors.
Cell culture and chondrogenic differentiation
Primary chondrocytes were isolated from the surrounding
matrix as described previously [2]. The isolated cells were
seeded at 104cells/cm2 in culture flasks (cell passage 0; Cos-
tar; Corning Incorporated, Corning, NY, USA) in expansion
medium consisting of DMEM/Ham's F12 (Gibco, Paisley, Ren-
frewshire, UK) supplemented with L-ascorbic acid (0.025 mg/
ml; Apotekets production unit, Umeå, Sweden), gentamicin
sulphate (50 mg/l; Gibco, Paisley, Renfrewshire, UK), ampho-
tericin B (250 μg/ml; Gibco, Paisley, Renfrewshire, UK) and L-
glutamine (2 mM; Gibco, Paisley, Renfrewshire, UK) and 10%
human serum.
In order to induce chondrogenesis, cells in passage 2 were
cultured in either high-density pellet cultures or hyaluronan-
based biodegradable polymer scaffolds (Hyaff-11) developed
for tissue- engineering applications, as described previously
[15]. For pellet mass cultures, 2 × 105 cells in passage 2 were
placed into a conical polypropylene tube with 0.5 ml of defined
medium, consisting of DMEM high glucose (PAA Laborato-Available online http://arthritis-research.com/content/11/5/R133
Page 3 of 14
(page number not for citation purposes)
ries, Linz, Austria) supplemented with 5.0 μg/ml linoleic acid
(Sigma-Aldrich, Stockholm, Sweden), insulin-transferrin-sele-
nium-G (ITS-G; Gibco, Paisley, Renfrewshire, UK), 1.0 mg/ml
human serum albumin (Equitech-Bio, Kerrville, TX, USA), 10
ng/ml transforming growth factor beta 1 (TGF-β1; R&D Sys-
tems, Abingdon, UK), 10-7 M dexamethasone (Sigma-Aldrich,
Stockholm, Sweden), 14 μg/ml L-ascorbic acid (Apotekets,
Umeå, Sweden) and 1% penicillin-streptomycin (PEST, PAA
Laboratories, Linz, Austria). The cells were centrifuged at 500
g for five minutes and maintained in 37°C in 7% carbon diox-
ide/93% air with medium changes twice a week. For scaffold
culture, 2 × 106 cells/cm2 were seeded in Hyaff-11 scaffolds,
4 cm2 in size (Fidia Advanced Biopolymers, Abano Terme,
Italy), pre-coated with human serum.
After 14 days of chondrogenic differentiation, the specimens
were fixed in Histofix™ (Histolab products AB, Gothenburg,
Sweden), dehydrated with ethanol, and embedded in paraffin.
Five-micrometer sections were cut and placed onto silane-
coated glass slides (Superfrost Plus, Menzel-Gläser, Ger-
many). The sections were deparaffinized and stained with
Alcian Blue van Gieson and Safranin-O, and were then
observed with a light microscope (Nikon, Tokyo, Japan). Chon-
drogenesis was further analyzed using the Bern Score as
described previously [16]. Briefly, this scoring system
assesses the uniformity and intensity of matrix staining, cell
density/extent of matrix produced, and cellular morphologies,
which is graded according to the Bern Score scale. The
results for the single observations of each assessed ND and
OA sample were averaged and used for statistical analysis.
Differentiation was also studied by immunohistochemical
localization of collagen types I and II as described below.
Immunohistochemistry
The expression of collagen types I and II was studied in both
pellet and scaffold cultures. Sections of the pellets were
deparaffinized, dehydrated, digested with 8000 U/ml hyaluro-
nidase (Sigma-Aldrich, Stockholm, Sweden) in PBS for one
hour at 37°C and blocked with 3% BSA (Sigma-Aldrich,
Stockholm, Sweden). Then, sections were labeled with pri-
mary monoclonal antibodies raised against collagen types I
and II (anti-collagen type I and II (ICN Biomedicals, Aurora,
OH, USA)) diluted 1:150. Subsequently, primary antibodies
were visualized using a horseradish peroxidase-conjugated
secondary antibody (goat-anti-mouse) (Jackson Laboratory,
Maine, ME, USA), diluted 1:150. All incubations were per-
formed at room temperature in a humidified chamber for one
hour. Horseradish peroxidase, and therefore also the second-
Figure 1
Schematic illustration of experimental setup Schematic illustration of experimental setup.  Articular chondrocytes from three patients with osteoarthritis and from three patients undergoing autol-
ogous chondrocyte transplantation (ACT) were isolated applying protocols used for ACT. After expansion in monolayer the chondrogenic differenti-
ation potential was evaluated in high-density pellet and scaffold (Hyaff-11) cultures by histological assessment (Bern Score, immunohistochemistry 
for collagen types I and II). Chondrocytes cultured in monolayer and scaffolds were subjected to comparative gene expression analysis (genome-
wide oligonucleotide microarrays, real-time PCR).Arthritis Research & Therapy    Vol 11 No 5    Dehne et al.
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ary antibodies, were visualized using the TSA-Direct Cy3 kit
(Perkin Elmer, Boston, MA, USA) according to the manufac-
turer's instructions. Nuclei were stained with 4',6-Diamidino-2-
phenylindol (Sigma-Aldrich, Stockholm, Sweden) and the
slides were mounted in antifading medium. The sections were
then analyzed using a fluorescence microscope (Nikon, Tokyo,
Japan) and digital pictures were taken with the ACT-1 soft-
ware (Nikon, Tokyo, Japan). Positive controls were sections
from goat hyaline cartilage obtained from the knee and nega-
tive controls were sections incubated with only secondary
antibody.
RNA isolation
Total RNA from chondrocytes cultured in monolayer (ML; pas-
sage 2) was isolated applying protocols for animal tissues of
the RNeasy Mini Kit (Qiagen, Hilden, Germany). For scaffold
cultures, an 8 mm punch was prepared, snap-frozen in liquid
nitrogen, and stored at -80°C until further use. Frozen samples
were transferred to 1 ml TriReagent (Sigma-Aldrich, Stock-
holm, Sweden) and mechanically homogenized. Subse-
quently, 133 μl 1-Bromo-3-chloro-propane (Sigma-Aldrich,
Stockholm, Sweden) was admixed followed by centrifugation
for 45 minutes at 13,000 g. The aqueous phase was collected
and nucleic acids were precipitated by addition of an equal
volume of ice-cold isopropanol. After 30 minutes incubation
the precipitated nucleic acids were pelleted and resolved in
350 μl RLT buffer (Qiagen, Hilden, Germany). Further purifica-
tion was performed according to protocols for animal tissues
of the RNeasy Mini Kit (Qiagen, Hilden, Germany).
Microarray analysis
RNA from ML and scaffold cultures was subjected to gene
expression analysis using oligonucleotide microarray HG-
U133plus2.0 (Affymetrix, Santa Clara, CA, USA) according to
the manufacturer's recommendations. Briefly, 2 μg of total
RNA were used to synthesize biotin-labeled cRNA. Ten micro-
gram samples of fragmented cRNA were hybridized to Gene-
Chips for 16 hours at 45°C. Washing, staining and scanning
of the microarrays were performed using the Affymetrix Gene-
Chip equipment (Santa Clara, CA, USA). Raw expression data
were normalized and subsequently analyzed with the Gene-
Chip Operating Software 1.4 (GCOS, Affymetrix, Santa Clara,
CA, USA). For comparative analysis the workflow imple-
mented in the SiPaGene database was applied [17]. In detail,
samples of each scaffold culture (three-dimensional (3D))
were compared with ML cultures as baseline, for OA and ND
separately. Furthermore, OA ML and 3D cultures were com-
pared with corresponding ND cultures as baseline (for sche-
matic illustrations of comparative analysis see Figure 1).
Genes were regarded as differentially regulated when fulfilling
specific change call criteria. The limit was set to at least eight
(of nine possible) significant change calls. Functional classifi-
cation was conducted with annotations from the Gene Ontol-
ogy Annotation Database [18]. Expression differences were
given as fold changes (FC). The significance level was deter-
mined applying the Welch's t-test on log2-transformed signal
values. Hierarchical cluster analysis was performed with log2-
transformed signals normalized by genes and Pearson corre-
lation as distance measure using Genesis 1.7.2 software
(Graz University of Technology, Institute for Genomics and
Bioinformatics, Graz, Austria) [19]. Microarray data have been
deposited in the National Center for Biotechnology Informa-
tion Gene Expression Omnibus and are accessible through
Gene Expression Omnibus series accession number
[GSE16464].
Real-time PCR
Equal amounts of the remaining RNA not used for microarray
analysis were reverse transcribed with the iScript cDNA syn-
thesis kit (BioRad, München, Germany). cDNA was amplified
using SYBR green PCR reagents (Applied Biosystems, Darm-
stadt, Germany) and the iCycler (BioRad, München, Ger-
many). The expression of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used to normalize samples by
adjusting the sample cDNA concentration. Marker gene
expression (Table 1) is given as a percentage related to
GAPDH expression [20].
Results
Histology and immunohistochemistry
After 14 days of differentiation, intense Alcian Blue van Gieson
staining was detected in pellets from both ND (Figure 2a) and
OA (Figure 2b) chondrocytes, demonstrating accumulation of
sulphated proteoglycans. A matrix containing collagen types I
(Figures 2c, d) and II (Figures 2e, f) was detected in these pel-
lets, but no differences were detected between ND (Figures
2c, e) and OA (Figures 2d, f) chondrocytes. Additionally,
applying the Bern Score system for histological assessment of
the pellets demonstrated that there were no significant differ-
ences in the cartilage quality between OA and ND chondro-
cytes (Figure 2g). A less differentiated phenotype was
detected in the scaffold-cultured cells, but accumulation of
sulphated proteoglycans was still detected using Alcian Blue
van Gieson in ND (Figures 3a, c) and OA (Figures 3b, d) cul-
tures. No significant differences in accumulation of a cartilagi-
nous matrix could be detected between OA and ND
chondrocytes cultured in scaffolds applying the Bern Score
(Figure 3m). Accumulation of both collagen types I (Figures 3e
to 3h) and II (Figures 3i to 3l) was detected in Hyaff-11 scaf-
folds seeded with either healthy (Figures 3e, g, i, k) or OA (Fig-
ures 3f, h, j, l) chondrocytes, no significant differences were
detected between the two cell sources. In accordance with
the Alcian Blue van Gieson staining, less accumulation of col-
lagen type II was detected in the Hyaff-11 scaffolds compared
with the high-density pellet cultures.
Comparative gene expression analysis
Comparative microarray analysis identified a total number of
1336 genes that were differentially regulated comparing ND
chondrocytes cultured in monolayer and scaffold culture, whileAvailable online http://arthritis-research.com/content/11/5/R133
Page 5 of 14
(page number not for citation purposes)
2534 genes were regulated making the same comparison for
OA chondrocytes (Table 2) [see Additional data file 1]. Fewer
genes were regulated comparing OA and ND chondrocytes
cultured in ML (661 genes regulated) and scaffold culture
(184 genes regulated). Further examination was performed on
the basis of genes associated with differentiation processes,
which were identified with annotations obtained from the
Gene Ontology Database (terms 'skeletal development' and
'extracellular matrix (ECM) formation) [see Additional data file
2]. This resulted in a selection of genes coding for collagens,
proteoglycans, matrix-modifying enzymes, cell attachment
components, growth factors, surface receptors, and transcrip-
tion factor. Initially, the expression profiles of ND chondrocytes
during ML culture (baseline) and Hyaff-11 culture were gener-
ated and compared. Secondly, significantly regulated genes
obtained in the initial analysis were used as reference to study
OA chondrocytes cultured in ML and scaffolds.
Gene expression profiling during normal donor 
differentiation
One hundred and seven genes were found differentially
expressed comparing ND scaffold cultures with ND chondro-
cytes cultured in ML (baseline) [see Additional data file 2].
Scaffold culture resulted in a significantly increased expres-
sion of cartilage markers such as collagen type IIα1
(COL2A1) and cartilage oligomeric matrix protein (COMP),
about 80-fold and 120-fold, respectively (Table 3). Expression
of the proteoglycans aggrecan (ACAN) and cartilage link pro-
tein 1 (CRTL1) was also increased but to a lower extent (> 2-
fold). The same expression pattern was detected for collagen
types IXα2 (COL9A2) and XIα1 (COL11A1), that expression
was both significantly increased as the ND chondrocytes dif-
ferentiated (> 4-fold). Also structural components of the carti-
lage ECM including dermatopontin (DPT), asporin (ASPN),
biglycan (BGN), cartilage intermediate protein 2 (CILP2),
fibromodulin (FMOD), tenascin C (TNC) and  fibronectin
(FN1) showed a significant increase in expression (3.3 to 67-
fold) during 3D culture. The expression of different genes cod-
ing for ECM degrading enzymes, such as a desintegrin and
metalloproteinase with thrombospondin motifs (ADAMTS)-2
(3.1-fold) and matrix metalloproteinase (MMP)-2  (1.9-fold),
and MMP7 (109-fold), altogether involved in active matrix turn-
over of differentiating cells, was increased. On the contrary,
the expression of ADAMTS12 (13-fold), ADAMTS5 (8-fold),
and MMP1 (10-fold) was repressed while tissue inhibitor of
metalloproteinase (TIMP)-4 (14-fold) was induced. Expres-
sion of growth factors including insulin-like growth factor
(IGF)-1  (8-fold) and IGF2  (40-fold) was highly increased.
TGF-β1 (4-fold) and bone morphogenetic protein (BMP)-1
(2.1-fold) expression was increased to a lower extent and the
same expression pattern could be detected for growth factor
receptors including TGFβ receptor 1 (TGFBR1) and fibrob-
last growth factor receptor 2 (FGFR2). Expression of a large
number of transcription factors such as members of the home-
obox (HOX), SRY (sex determing region)-box (SOX), distal-
less homeobox, and wingless-type MMTV integration site
gene families was induced during differentiation. Of special
interest is the increased expression of SOX9 (4.4-fold), which
acts as a direct regulator of COL2A1 expression. Another
transcription factor that was found to be increased (> 4-fold)
was runt-related transcription factor 2 (RUNX2), known to be
involved in several differentiation processes. Taken together,
scaffold culture facilitated the induction of relevant marker
genes for chondrogenic differentiation in ND chondrocytes.
Gene expression analysis of chondrogenic potential of 
OA chondrocytes
The expression pattern of genes identified during ND chondro-
cyte differentiation was analyzed in cells obtained from
patients with OA. Eighty five of the 107 genes significantly
regulated during ND chondrocyte differentiation qualitatively
displayed the same expression pattern during OA chondro-
Table 1
Primer oligonucleotide sequences used for real-time PCR
Gene Forward primer 5'-3' Reverse primer 5'-3' Accession number
COL1A1 CGATGGCTGCACGAGTCACAC CAGGTTGGGATGGAGGGAGTTTAC [GenBank:NM_000088]
COL10A1 GAACTCCCAGCACGCAGAATCC GTGTTGGGTAGTGGGCCTTTTATG [GenBank:NM_000493]
COL2A1 CCGGGCAGAGGGCAATAGCAGGTT CATTGATGGGGAGGCGTGAG [GenBank:NM_001844]
COMP GGGTGGCCGCCTGGGGGTCTT CTTGCCGCACGCTGATGGGTCTC [GenBank:NM_000095]
CRTL1 GCGTCCGCTACCCCATCTCTA GCGCTCTAAGGGCACATTCAGTT [GenBank:NM_001884]
GAPDH GGCGATGCTGGCGCTGAGTAC TGGTTCACACCCATGACGA [GenBank:NM_000095]
MMP1 TACATGCGCACAAATCCCTTCTACC GAAAAACCGGACTTCATCTCTGTCG [GenBank:NM_002421]
MMP13 CAAAAACGCCAGACAAATGTGACC GATGCAGGCGCCAGAAGAATCT [GenBank:NM_002427]
SOX9 CTGAGTCATTTGCAGTGTTTTCT CATGCTTGCATTGTTTTTGTGT [GenBank:NM_000346]
TIMP4 TTTCTTCTGGCTTAGTCTGTTTTCT ATTCGCCATTTCTCCCCTACCA [GenBank:NM_003256]Arthritis Research & Therapy    Vol 11 No 5    Dehne et al.
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cyte differentiation. COL2A1 was increased about 500-fold
and COMP nearly 800-fold (Table 3) demonstrating a signifi-
cantly higher increase in expression during differentiation com-
pared with ND chondrocytes. Expression of other ECM
components such as COL9A2 (8-fold) and COL11A1 (6-fold)
as well as proteoglycans such as biglycan (12-fold), dermat-
opontin (44-fold), and aggrecan (3.4-fold) was also signifi-
cantly upregulated as the OA cells differentiated (Table 3). As
the expression profiles of OA and ND chondrocytes during dif-
ferentiation do not completely overlap, OA-related differences
were analyzed in more detail as described below.
Figure 2
Histology of normal donor and osteoarthritic chondrocyte pellet cul- tures Histology of normal donor and osteoarthritic chondrocyte pellet cul-
tures.  Chondrogenic differentiation of chondrocytes obtained from (a, 
c, e) normal donors (ND) and (b, d, f) osteoarthritic (OA) articular carti-
lage using the high-density pellet culture system. (a, b) Alcian Blue van 
Gieson staining and immunohistochemical localization of (c, d) colla-
gen type I and (e, f) type II. (g) Bern Score evaluating the differentiation 
grade of the cells. Three cultures per donor group.
Figure 3
Histology of osteoarthritic and normal chondrocyte scaffold culture Histology of osteoarthritic and normal chondrocyte scaffold culture.  
Chondrogenic differentiation of chondrocytes obtained from (a, c, e, g, 
i, k) normal and (b, d, f, h, j, l) osteoarthritic (OA) articular cartilage cul-
tured in Hyaff-11 scaffolds. (a to d) Alcian Blue van Gieson staining, 
immunohistochemical localization of collagen (e to h) type I and (I to l) 
type II, with (g, h, k, l) higher magnification, and (m) Bern Score, * scaf-
fold fibre, # cell nuclei. Three cultures per donor group.Available online http://arthritis-research.com/content/11/5/R133
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Gene expression analysis of OA and ND chondrocytes 
cultured in monolayer
Comparing monolayer cultures of OA and ND chondrocytes,
expression of 32 genes related to skeletal development was
detected as changed [see Additional data file 2]. Among them,
COMP (6-fold), FN1 (3.1-fold), TIMP3 (2.1-fold), TGFBR2
(1.8-fold) and SOX9 (2.6-fold) were expressed at lower levels
in OA chondrocytes, whereas MMP1 (5-fold) and MMP3 (2.6-
fold), as well as the matrix components COL5A3 (2.9-fold),
COL3A1  (2.2-fold) and periostin  (1.9-fold) displayed an
increased expression in OA chondrocytes (Table 4).
Gene expression analysis of OA and ND chondrocytes 
cultured in Hyaff-11 scaffolds
In scaffold cultures, only 17 genes related to differentiation
and ECM were differentially expressed. Among those genes,
which were already discussed, only FN1 (1.8-fold), dystonin
(DST) (3.5-fold), and TIMP3 were still differentially expressed;
however, expression of FN1 and DST was reversed compared
with ML (Table 4). Altogether, the differences detected
between OA and ND chondrocytes cultured in ML were fur-
ther diminished as the cells differentiated in Hyaff-11 scaf-
folds.
Considering the expression pattern of ND chondrocytes, hier-
archical clustering resulted in two main groups, classified as
ML and scaffold (Figure 4). The clustering also showed that
the ML-cultured OA and ND chondrocytes clustered, while no
such clustering was detected in cells cultured in Hyaff-11 cul-
ture. Additionally, the total number of genes (without functional
filtering) differentially expressed between OA and ND
chondrocytes was remarkable reduced in scaffold culture
(184) in comparison with ML (661 genes; Table 2) [see Addi-
tional data file 1].
PCR validation of microarray results
In order to confirm expression profiles as assessed by micro-
array analysis, the expression of selected genes was analyzed
by real-time PCR (Figure 5). Expression of the cartilage mark-
ers COMP and SOX9 was found to be highly induced during
scaffold culture, as also seen in the microarray analysis.
COL2A1 and CRTL1 were also highly expressed in scaffold
culture but with more donor-dependent variations. COL10A1
expression, associated with cartilage hypertrophy, was also
increased during scaffold culture, but no difference between
OA and ND chondrocytes was detected. In contrast, the
expression of MMP1 was higher in OA chondrocytes cultured
in ML compared with ND chondrocytes. The expression of this
gene was then significantly reduced in scaffold culture in both
groups of donors to a comparable level. No significant differ-
ences in expression of MMP13 and COL1A1 were detected
comparing cells cultured in ML or scaffolds as well as compar-
ing OA and ND chondrocytes. Taken together, PCR analysis
demonstrated the same gene expression pattern as the micro-
array analysis in all nine genes analyzed by real-time PCR.
Discussion
In order to be able to use second-generation ACT techniques
for the repair of cartilage defects in patients with OA, it is
highly important to investigate whether OA chondrocytes have
an irreversibly altered phenotype or if these cells can differen-
tiate towards a hyaline cartilage phenotype after in vitro expan-
sion. Today, there are conflicting data whether OA
chondrocytes fulfill the prerequisites for ACT treatment or not
[12,13,15,21]. This encouraged us to investigate more thor-
oughly the chondrogenic differentiation potential of human OA
chondrocytes using microarray technology in order to deter-
mine whether OA chondrocytes might possibly be used in
second-generation ACT.
Microarray analysis of human OA and ND chondrocytes cul-
tured in ML indicated that the OA chondrocytes were in a less
differentiated state compared with the ND chondrocytes. This
is thus in accordance with the differences detected in vivo
between OA and ND cartilage [10,22]. Re-differentiation in
scaffold cultures diminished these differences, demonstrating
Table 2
Overview of number of genes differentially expressed in chondrocyte monolayer and scaffold culture
3D vs ML OA vs ND
Significance level ND OA ML 3D
GCOS 107 (1336) 152 (2534) 32 (661) 17 (184)
+ P < 0.05 60 (724) 110 (1723) 7 (331) 1 (12)
+ P < 0.01 24 (217) 43 (613) 0 (78) 0 (1)
+ P < 0.001 3 (27) 8 (92) 0 (10) 0 (0)
Comparisons between scaffold (3D) and monolayer (ML) cultures were performed for chondrocytes obtained from osteoarthritic (OA) and normal 
donors (ND) (see Figure 1 for experimental setup). Genes were functionally filtered by annotations of the Gene Ontology Database according to 
their association with skeletal development and extracellular matrix formation [see Additional data file 2 for full list]. Genes were regarded as 
differentially expressed when fulfilling specific change call criteria provided by GeneChip Operating Software (GCOS, Affymetrix). The limit was 
set to at least eight (of nine possible) significant change calls. Further significance levels were determined applying the Welch's t-test of the 
SiPaGene database [17]. Numbers in brackets represent the total number of genes regulated without functional filtering [see Additional data file 
1 for full list].Arthritis Research & Therapy    Vol 11 No 5    Dehne et al.
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Table 3
Classification of genes that are differentially expressed in chondrocyte monolayer (baseline) and scaffold culture
Functional annotation
Gene title (Gene symbol)
Accession number Fold change
Scaffold vs Monolayer
Normal donors OA donors
Extracellular matrix
Aggrecan (ACAN) [GenBank:X17406]2 . 0 3 . 4  * *
Asporin (ASPN) [GenBank:NM_017680] 18.8 * 6.0 *
Biglycan (BGN) [GenBank:NM_001711] 12.5 12.7 *
Cartilage intermediate layer protein 2 (CILP2) [GenBank:BC034926] 78.2 * 71.3 *
Collagen, type II, alpha 1 (COL2A1) [GenBank:X06268] 87.1 519.9 **
Collagen, type XI, alpha 1 (COL11A1) [GenBank:BG028597] 10.4 ** 5.9 *
Collagen, type IX, alpha 2 (COL9A2) [GenBank:AI733465]4 . 38 . 1
Cartilage link protein 1 (CRTL1) [GenBank:NM_001884]2 . 5 1 . 8
Cartilage oligomeric matrix protein (COMP) [GenBank:NM_000095] 128.0 ** 794.2 ***
Dermatopontin (DPT) [GenBank:AL049798] 69.7 ** 44.2 ***
Fibromodulin (FMOD) [GenBank:NM_002023]5 . 1 8 . 4  *
Fibronectin 1 (FN1) [GenBank:AJ276395]5 . 7  * 3 4 . 6  * * *
TIMP metalloproteinase inhibitor 4 (TIMP4) [GenBank:NM_003256] 14.1 * 25.4 *
Tenascin C (TNC) [GenBank:BF434846]3 . 33 . 5  *
Cell adhesion and receptors
Epidermal growth factor receptor (EGFR) [GenBank:AW157070]- 3 . 0  * * - 1 . 9
Fibroblast growth factor receptor 2 (FGFR2) [GenBank:NM_022969] -7.4 * -4.3
Laminin, alpha 2 (LAMA2) [GenBank:AK026829]5 . 7  * 4 . 8
Laminin, alpha 4 (LAMA4) [GenBank:NM_002290] -6.6 * -8.6 **
Transforming growth factor, beta receptor I (TGFBR1) [GenBank:AV700621]4 . 2 2 0 . 0  * * *
Thrombospondin 3 (THBS3) [GenBank:L38969]8 . 2  * * 8 . 5  *
Growth factors
Bone morphogenetic protein 1 (BMP1) [GenBank:NM_001199]2 . 1  * 1 . 8
Fibroblast growth factor 9 (FGF9) [GenBank:NM_002010]- 9 . 0 - 3 . 0
Insulin-like growth factor 1 (IGF1) [GenBank:AI972496]8 . 36 . 0
Insulin-like growth factor 2 (IGF2) [GenBank:X07868] 114.9 ** 43.5 **
Transforming growth factor, beta 1 (TGFB1) [GenBank:BC000125]3 . 0  * 2 . 4  *
Transcription factors
Distal-less homeobox 5 (DLX5) [GenBank:NM_005221]5 . 1  * 2 5 . 6  *
Homeobox A11 (HOXA11) [GenBank:H94842]6 . 5 2 . 3  *
Homeobox A13 (HOXA13) [GenBank:BG289306]5 . 2 2 . 0
Runt-related transcription factor 2 (RUNX2) [GenBank:AL353944]4 . 04 . 2  *
SIX homeobox 1 (SIX1) [GenBank:N79004]1 . 6  * 1 . 3
SIX homeobox 4 (SIX4) [GenBank:AI554514]1 . 82 . 3
SRY (sex determining region Y)-box 9 (SOX9) [GenBank:NM_000346]4 . 4  * * 1 1 . 8  * *
Wingless-type MMTV integration site family, member 5B (WNT5B) [GenBank:AW007350]3 . 0 7 . 0
Enzymes
ADAM metalloproteinase with thrombospondin type 1 motif, 12 (ADAMTS12) [GenBank:W74476]- 1 3 . 7  * * - 2 . 4
ADAM metalloproteinase with thrombospondin type 1 motif, 2 (ADAMTS2) [GenBank:NM_021599]3 . 1 4 . 7  * *
ADAM metalloproteinase with thrombospondin type 1 motif, 5 (ADAMTS5) [GenBank:BF060767] -8.8 * -7.6 **
Matrix metalloproteinase 1 (MMP1) [GenBank:NM_002421] -10.6 ** -59.7
Matrix metalloproteinase 2 (MMP2) [GenBank:NM_004530]1 . 9  * 3 . 4  *
Matrix metalloproteinase 7 (MMP7) [GenBank:NM_002423] 109.7 *** 107.2 **
One hundred and seven genes associated with skeletal development and extracellular matrix formation were found differentially expressed in 
chondrocytes obtained from normal donors cultured in monolayer (baseline) and scaffolds. The expression patterns of these genes were 
compared with those of differentiating osteoarthritic (OA) chondrocytes to assess the chondrogenic capacity of these cells. Only genes are 
presented that belong to the shown functional categories. For the complete list see Additional data file 2. * P < 0.05; ** P < 0.01; *** P < 0.001.Available online http://arthritis-research.com/content/11/5/R133
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that only 17 genes related to skeletal development were sig-
nificantly differentially expressed between both groups. This
high similarity was not only detected on gene expression level
but also in their ability to accumulate sulphated proteoglycans
and collagen type II, matrix components characteristic for a
hyaline cartilage phenotype. High-density pellet cultures con-
Table 4
Genes differentially expressed comparing chondrocytes in culture obtained from osteoarthritic (OA) and normal donors (ND)
Functional annotation
Gene title (Gene symbol)
Accession number Fold change Signal
OA vs ND OA ND
Monolayer
ADAM metalloproteinase with thrombospondin type 1 motif, 1 (ADAMTS1) [GenBank:AF060152] -1.7 968.0 1925.2
Collagen, type III, alpha 1 (COL3A1) [GenBank:AU146808] 2.2 564.3 258.7
Collagen, type V, alpha 3 (COL5A3) [GenBank:AI984221] 2.9 977.6 392.1
Collagen, type XI, alpha 1 (COL11A1) [GenBank:BG028597] 1.9 327.8 161.1
Cartilage link protein 1 (HAPLN1) [GenBank:NM_001884] 1.8 * 2640.7 1467.5
Cartilage oligomeric matrix protein (COMP) [GenBank:NM_000095] -6.1 * 24.7 187.4
Dystonin (DST) [GenBank:BC004912] -2.0 729.4 1486.6
Fibronectin 1 (FN1) [GenBank:AJ276395] -3.1 441.9 1642.6
Matrix metalloproteinase 1 (MMP1) [GenBank:NM_002421] 5.0 * 857.0 200.5
Matrix metalloproteinase 2 (MMP2) [GenBank:NM_004530] -1.9 2300.1 3706.1
Matrix metalloproteinase 3 (MMP3) [GenBank:NM_002422] 2.6 2496.8 1052.8
Periostin, osteoblast specific factor (POSTN) [GenBank:AY140646] 1.9 6610.8 3544.5
SRY (sex determining region Y)-box 9 (SOX9) [GenBank:AI382146] -2.6 * 123.0 281.2
Transforming growth factor, beta receptor II (TGFBR2) [GenBank:D50683] -1.8 970.0 1760.5
TIMP metalloproteinase inhibitor 3 (TIMP3) [GenBank:NM_000362] -2.1 524.5 1067.1
Scaffold
Collagen, type VI, alpha 1 (COL6A1) [GenBank:BE350145] 1.6 1125.6 767.4
Collagen, type VIII, alpha 2 (COL8A2) [GenBank:AI806793] -1.5 749.8 1067.1
Catenin, beta 1 (CTNNB1) [GenBank:AF130085] 1.8 1254.4 785.5
Dystonin (DST) [GenBank:BC004912] 1.8 1969.3 1178.2
Fibulin 1 (FBLN1) [GenBank:Z95331] -1.3 557.5 728.4
Fibronectin 1 (FN1) [GenBank:W73431] 3.5 1160.8 410.2
Homeobox A13 (HOXA13) [GenBank:BG289306 -2.1 30.5 62.8
Homeobox C6 (HOXC6) [GenBank:NM_004503] 1.8 857.2 525.7
Latent transforming growth factor beta binding protein 1 (LTBP1) [GenBank:AI986120] 1.6 997.6 646.6
Myocyte enhancer factor 2C (MEF2C) [GenBank:N22468] 1.7 * 498.1 296.5
Microfibrillar-associated protein 2 (MFAP2) [GenBank:NM_017459] -1.4 2875.4 4083.6
Tissue factor pathway inhibitor 2 TFPI2) [GenBank:AL574096] 2.8 76.2 38.3
Transforming growth factor, beta receptor I (TGFBR1) [GenBank:AV700621] 2.6 682.7 303.9
TIMP metalloproteinase inhibitor 3 (TIMP3) [GenBank:BF347089] -1.5 216.2 308.3
WNT1 inducible signaling pathway protein 3 (WISP3) [GenBank:AF143679] -2.0 318.5 549.8
Genes were functionally filtered with regard to their association with skeletal development and extracellular matrix formation. For the complete list 
see Additional data file 1. * P < 0.05; ** P < 0.01; *** P < 0.001.Arthritis Research & Therapy    Vol 11 No 5    Dehne et al.
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firmed these results, demonstrating differentiation towards the
hyaline cartilage lineage for both ND and OA chondrocytes.
Differentiation in the scaffolds was for both ND and OA
chondrocytes associated with significantly increased expres-
sion of matrix constituents characteristic for mature articular
cartilage, including aggrecan, biglycan, CILP2, COL2A1,
COL9A2, COL11A1, COMP, and FN1 [23-27]. Another sign
of chondrogenic differentiation was the increased expression
of TGFB1 as well as DPT, which have been demonstrated to
increase the cellular response to TGFβ [28,29]. In contrast,
COMP,  FN1, and SOX9  displayed a reduced expression
while COL3A1, MMP1 and MMP3 showed increased expres-
sion in OA chondrocytes compared with ND chondrocytes
cultured in ML. Except for TIMP3, no significant differences
were consistently detected between OA and ND chondro-
cytes after 14 days of re-differentiation in scaffolds consider-
ing a gene set relevant for differentiation.
An increased expression of the hypertrophic cartilage marker
COL10A1 gene has been reported in OA cells in comparison
to normal chondrocytes, which might limit their use in tissue
engineering [11]. However, our results did not demonstrate a
significant difference in the expression of COL10A1 between
normal and OA chondrocytes in scaffold culture, neither did
we detect any differences in the expression of markers for
endochondral bone formation including alkaline phosphatase,
parathyroid hormone receptors 1 and 2, periostin and RUNX2
[30-33]. The induction of genes such as COL10A1  and
RUNX2 in our scaffold cultures is primarily caused by the use
of the chondrogenic factor TGF-β1, which was also observed
in chondrogenically induced micromasses of chondrocytes or
mesenchymal stem cells [34-36]. This model-inherent
COL10A1 induction does not inhibit the detection of different
COL10A1 expression levels as shown by Tallheden and col-
leagues [15], and maybe can be inhibited by the addition of
factors such as parathyroid hormone-related protein [37].
Accordingly, the risk of differentiation into the hypertrophic
cartilage lineage thus does not seem to be increased for the
OA chondrocytes. In accordance with our results, Stoop and
colleagues recently demonstrated that ML expanded normal
and OA chondrocytes transplanted subcutaneously into
immunodeficient mice for eight weeks displayed no significant
differences in their expression of aggrecan, COL1A1,
COL2A1, or COL10A1 [14]. Our results further demonstrate
that the expression of matrix proteins characterizing the phe-
notypical alteration of OA chondrocytes, that is, increased
expression of COL1A1, COL3A1, TNC [38-40], did not dis-
play a significantly higher expression in OA chondrocytes
compared with normal chondrocytes, either after ML culture or
in scaffolds. This suggests that the cells have already acquires
a normal phenotype after the second passage. These results
are in accordance with Yang and colleagues, who demon-
strated diminishing differences on mRNA level from passage
1 to 2 between normal and OA chondrocytes [41]. The same
results were obtained for several MMPs, TIMPs, and ADAMs
that are differentially regulated between OA and normal carti-
lage [42,43]. Interestingly, we detected that MMP13, which is
the principal degradative enzyme for collagen types I, II and III
Figure 4
Hierarchical cluster analysis of chondrocytes from osteoarthritic and normal donors cultured in monolayer and Hyaff-11 scaffolds Hierarchical cluster analysis of chondrocytes from osteoarthritic and normal donors cultured in monolayer and Hyaff-11 scaffolds.  Genes that were 
differentially expressed between normal donors (ND) chondrocytes cultured in monolayer (ML) and scaffold (3D) cultures, functionally filtered by 
their association with skeletal development and extracellular matrix (ECM) formation, were used to assess chondrogenic capacity of chondrocytes 
from osteoarthritic (OA) patients. Green bars depict a repressed and red bars an induced expression of genes normalized to the mean. The cluster-
ing gave two main groups classified as monolayer chondrocytes and scaffold-cultured chondrocytes. The separate OA monolayer cluster clearly 
indicated a differential expression pattern between OA and ND chondrocytes. In scaffold cultures on the other hand, no OA-related cluster separa-
tion was observed demonstrating a loss of differences between OA and ND chondrocytes during scaffold culture.Available online http://arthritis-research.com/content/11/5/R133
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in OA [44], has a somewhat altered expression in OA
chondrocytes than in the ND chondrocytes after expansion,
but this difference was diminished after re-differentiation. Like-
wise, hierarchical clustering analysis of genes relevant for dif-
ferentiation demonstrated diminishing differences in gene
expression from ML to differentiation in scaffolds, further sug-
gesting that differences between OA and ND chondrocytes
are decreased during re-differentiation in scaffolds. We thus
conclude that after expansion and re-differentiation the
chondrocytes from OA patients are not significantly different
from those from normal donors used in ACT. At this point, we
want to point out that mRNA expression do not always reflect
protein secretion. Nevertheless, 3D culture in high-density
micromasses or scaffolds seem to be appropriate to further
stabilize the chondrocyte phenotype without additional manip-
ulation of the cells.
Some of the differentially expressed genes in ML seem to be
OA-related, and thus may serve as OA indicators in vitro.
Especially genes coding for secreted proteins such as ECM
components, growth factors and degradative enzymes could
be of interest for the establishment of a non-destructive detec-
tion assay to ensure cell and culture quality, identity and purity.
Increased expression of MMP1 and MMP3 [45] as well as
type III and type V collagen expression [46] has been shown
to be associated with OA-related cartilage destruction. In con-
trast, an induction of MMP13 and COL2A1 during OA pro-
gression in native cartilage was described [47,48], but both
Figure 5
Real-time PCR verification of results from the microarray analysis Real-time PCR verification of results from the microarray analysis.  The expression was calculated as percentage of the expression of the housekeep-
ing gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The mean of each technical triplicate is plotted and the error bars represent stand-
ard deviation. * P < 0.05; ** P < 0.01; *** P < 0.001.Arthritis Research & Therapy    Vol 11 No 5    Dehne et al.
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genes were not found to be differentially expressed in ML in
our study, and thus seem not to be appropriate to distinguish
between normal and OA chondrocyte subcultures.
In this study, an estrified hyaluronic acid-based scaffold was
used as a vehicle for re-differentiation of the chondrocytes
because it has been used successfully in matrix-assisted car-
tilage repair in combination with culture-expanded chondro-
cytes [7,49]. Compared with pellet cultures, scaffold cultures
demonstrated a less differentiated phenotype on protein level
after 14 days of in vitro culture, but on gene expression level
the typical pattern of chondrogenic differentiation was
detected indicating a delayed differentiation in scaffold cul-
ture. This delay is not necessarily disadvantageous in clinical
practice. One important factor in ACT is the integration of the
scaffold to the surrounding cartilage and subchondral bone. It
was recently demonstrated by Obradovic and colleagues that
integration of the scaffold is dependent on the differentiation
grade of the cells [50]. Less differentiated tissue engineered
cartilage implants (re-differentiated for five days) demon-
strated better integration properties compared with mature
implants (re-differentiated for five weeks). The fact that the
cells were less differentiated in the scaffolds might thus be an
advantage for its clinical use. In clinical practice of Hyaff-11
scaffolds, prior ACT treatment the chondrocytes are differen-
tiated for 14 days and attain a differentiation grade similar to
the one obtained in our cultures. Other clinically matrix-associ-
ated ACT techniques also made use of seeding less differen-
tiated chondrocytes with comparable outcome further
confirming that transplantation of less differentiated chondro-
cytes is not a disadvantage [3,5,6].
One important issue, that in the context of a clinical application
needs to be further investigated, is the impact of the inflamma-
tory environment in OA cartilage on the transplanted chondro-
cytes. Cytokines, including IL-1 and TNF-α, are secreted by
OA cartilage. Such cytokines are known to induce cartilage
degradation and to reduce collagen type II expression [51].
These factors might not only degrade articular cartilage, but
may also affect the transplant. To ensure good clinical results,
it seems to be highly important to control the inflammatory
environment, for example by treating the patient with cytokine
inhibitors as well as removing any degenerated cartilage sur-
rounding the defect.
The emerging interest of cell-based regeneration of OA has
lead to the first systematic clinical considerations. Hollander
and colleagues reported tissue regeneration when tissue engi-
neered cartilage was implanted in injured and OA human
knees [21]. Ossendorf and colleagues performed a study on
short-term and mid-term efficacy of second-generation ACT
for treatment of degenerative cartilage defects [5]. Both sug-
gested that this technique is an effective treatment option for
the regeneration of OA defects of the knee, and OA does not
inhibit the regeneration process.
Our findings were made on a rather small individual basis com-
paring only a few individuals per group. We encountered this
lack of statistical power by having well-defined groups of car-
tilage donors (Mankin and Ahlbäck Scores, ND age matching),
and by applying detection techniques sensitive to identify sub-
tle distinctions in chondrogenic capacity (genome-wide micro-
array analysis, PCR, Bern Score). NDs meet the demands of
patients undergoing ACT treatment for isolated articular
lesions without further indications such as OA or inflammatory
diseases, in accordance with widely accepted treatment
guidelines [52]. ACT treatment is a method to repair focal car-
tilage lesions, which can occur as a result of traumatic
mechanical destruction. Chondrocytes from these patients
might thus slightly differ from chondrocytes obtained from
healthy joints. [53]. However, ACT patient-derived chondro-
cytes represent an ideal baseline when thinking about a further
development of ACT for treatment of OA patients. The OA
donors underwent hip replacement surgery and were accord-
ingly older (12 years in average age) than the ND donors. Bar-
bero and colleagues identified age-dependent differences in
the chondrogenic ability of expanded chondrocytes applying
the pellet assay. The chondrogenic capacity was decreased in
donors over 40 years of age compared with younger ones, but
no further significant decline of chondrogenic ability with
increasing age was observed [54], so that the difference in
age can be neglected. To ensure that even subtle distinctions
between ND and OA chondrocytes were detected, relaxed
selection criteria in comparative gene expression analysis
were applied. Thorough statistical analysis was performed to
reveal the significance level. Importantly, large-scale gene
expression analysis was performed applying a clinical relevant
model and appropriate settings. Therefore, our study provides
useful information, which is important for chondrocyte-based
cartilage repair procedures, especially in the discussion
whether chondrocyte differentiation potential is independent
of OA etiology or not.
Conclusions
Gene expression profiling indicated that chondrocytes from
OA donors showed a less differentiated state in ML compared
with ND chondrocytes. During 3D culture in scaffolds, the dif-
ferences in gene expression between OA and ND chondro-
cytes were diminished. Differences in expression of markers
for hypertrophic cartilage were not observed. Thus, OA
chondrocytes show a chondrogenic differentiation potential
comparable with ND chondrocytes and the risk of differentia-
tion into the hypertrophic cartilage lineage thus does not seem
to be increased. Our findings suggest that chondrocytes from
human OA cartilage fulfill the prerequisite for use in matrix-
assisted ACT.
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